您的位置: 首页 > 农业专利 > 详情页

CHIMERIC AND HUMANIZED ANTI-CD44 ANTIBODIES THAT MEDIATE CANCER CELL CYTOTOXICITY
专利权人:
F. HOFFMAN - LA ROCHE AG
发明人:
YOUNG, DAVID, S. F,FINDLAY, HELEN, P,HAHN, SUSAN, E,CECHETTO, LISA, M,MCCONKEY, FORTUNATA
申请号:
PH12014500679
公开号:
PH12014500679A1
申请日:
2014.03.26
申请国别(地区):
PH
年份:
2015
代理人:
摘要:
CD44, a single chain hyaluronic acid (HA) binding glycoprotein, is expressed in a variety of normal tissues, all hematopoietic cells and several cancer tissues. A monoclonal antibody against CD44 from the hybridoma H460-16-2, deposited with the ATCC as PTA-4621, was previously shown to be a cancerous disease modifying antibody (CDMAB), preventing tumour growth and reducing tumour burden in cancer models including prostate and breast cancer by cytotoxicity. The variable regions of this monoclonal antibody were also isolated and sequenced to generate a chimeric antibody that had improved anti- cancer activity over the monoclonal antibody. Now, humanized antibodies are generated that have similar CD44 binding activity as the parent PTA-4621 monoclonal antibody. The monoclonal, chimeric and humanized antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells to treat cancer. These antibodies are also used in binding assays to determine CD44 expression on cells.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充